A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

United States

Catalina Research Institute, LLC, Montclair, California

Catalina Research Institute, LLC, Rialto, California

Orlando Clinical Research Center, Orlando, Florida

Texas Liver Institute/Alamo Medical Research, San Antonio, Texas